scholarly journals Rarity of rpoB Mutations Outside the Rifampicin Resistance-Determining Region of Mycobacterium tuberculosis Isolates from Patients Responding Poorly to First-Line Tuberculosis Regimens in Beijing, China: A Retrospective Study

2021 ◽  
Vol Volume 14 ◽  
pp. 2607-2612
Author(s):  
Jidong Guo ◽  
Rongmei Liu ◽  
Jin Shi ◽  
Fengmin Huo ◽  
Yuanyuan Shang ◽  
...  
2016 ◽  
Vol 70 (4) ◽  
pp. 342-349 ◽  
Author(s):  
Feifei Yin ◽  
Jasper Fuk-Woo Chan ◽  
Qixuan Zhu ◽  
Ruijia Fu ◽  
Jonathan Hon-Kwan Chen ◽  
...  

AimsRapid and accurate diagnostic assays with simultaneous microbial identification and drug resistance detection are essential for optimising treatment and control of tuberculosis.MethodsWe developed a novel multiplex (TRIOL, Tuberculosis-Rifampicin-Isoniazid-Ofloxacin-Luminex) assay using the Luminex xMAP system that simultaneously identifies Mycobacterium tuberculosis and detects resistance to first-line and second-line anti-tuberculous drugs, and compared its performance with that by PCR sequencing, using phenotypic drug susceptibility testing as the gold standard.ResultsIdentification of M. tuberculosis by the TRIOL assay was highly sensitive (100%) and specific (100%). The overall drug-specific specificities were excellent (100%). The overall sensitivity of the TRIOL assay was lower than that of the PCR-sequencing assays (72.4% vs 82.8%) because of a lower sensitivity of detecting rifampicin resistance (71.4% vs 92.9%). The sensitivity of detecting isoniazid and ofloxacin resistance was as good as the PCR-sequencing assays. Importantly, the TRIOL assay did not miss any mutations that were included in the assay. All of the resistant isolates that were missed had uncommon mutations or unknown resistance mechanisms that were not included in the assay.ConclusionsThe TRIOL assay has higher throughput, lower cost and is less labour intensive than the PCR-sequencing assays. The TRIOL assay is advantageous in having the capability to detect resistance to multiple drugs and an open-architecture system that allows addition of more specific primers to detect uncommon mutations. Inclusion of additional primers for the identification of non-tuberculous mycobacteria, spoligotyping and improvement of rifampicin resistance detection would enhance the use of the TRIOL assay in future clinical and epidemiological studies.


2020 ◽  
Vol 20 (4) ◽  
pp. 491-494 ◽  
Author(s):  
Eltayib H. Ahmed Abakur ◽  
Tarig M.S. Alnour ◽  
Faisel Abuduhier ◽  
Fahad M.A. Albalawi ◽  
Khalid A.S. Alfifi

Purpose: Heteroresistant Mycobacterium tuberculosis (MTB) is defined as a group of drug-susceptible and resistant bacteria in a single clinical specimen from tuberculosis (TB) patients. Heteroresistance of MTB is considered a preliminary stage to full resistance. The present study aimed to determine the heteroresistance in Mycobacterium tuberculosis in Tabuk province, in the north of the Kingdom of Saudi Arabia. Method: GenoType MTBDRplus assay was used to determine mutations associated with isoniazid and rifampicin resistance. Results: A total number of 46 confirmed M. tuberculosis positive sputum samples were scanned for heteroresistance. The present study revealed 3 (6.5%) heteroresistant mutations to either rpoB gene alone, 2 (4.4%) to rpoB and 1 (2.2%) to inhA genes. Conclusion: The detection of heteroresistant mutations could guide the initiation of an appropriate regimen of treatment.


Author(s):  
Pedro Cortés ◽  
Hassan M. Ghoz ◽  
Obaie Mzaik ◽  
Muhamad Alhaj Moustafa ◽  
Yan Bi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document